Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

eLife

Rob Howes¹  Ashley Shaw²  Ben Warne³  Paul J Lehner³  Nicholas J Matheson⁴  Lucy Rivett⁵  Nick K Jones⁵  Michael P Weekes⁶  Ian G Goodfellow⁷  Shaun Seaman⁸  Giles Wright⁹  Mark Ferris⁹  Chris Workman⁹  Jo Wright⁹  Natalie Quinnell⁹  Richard J Samworth^1,10 

[1] Cambridge COVID-19 Testing Centre and AstraZeneca, Anne McLaren Building, Cambridge, United Kingdom;Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom;Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom;Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom;Department of Medicine, University of Cambridge, Cambridge, United Kingdom;Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom;Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom;Department of Medicine, University of Cambridge, Cambridge, United Kingdom;NHS Blood and Transplant, Cambridge, United Kingdom;Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom;Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom;Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom;Department of Medicine, University of Cambridge, Cambridge, United Kingdom;Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom;Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom;Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom;Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom;Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, Cambridge, United Kingdom;

关键词: SARS-CoV-2;    COVID-19;    BNT162b2;    vaccination;    asymptomatic;    Pfizer-BioNTech;    Human;   

DOI  :  10.7554/eLife.68808

来源: eLife Sciences Publications, Ltd

【 摘 要 】

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.

【 授权许可】

CC BY